Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force

Journal of Translational Medicine

Commentary

Samir N Khleif¹  Lisa H Butterfield²  Francesco M Marincola³  James M Balwit⁴  Mary L Disis⁵ 

[1] Cancer Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA;Infectious Disease and Immunogenetics Section (IDIS), Dept. of Translation Medicine, Clinical Center, and Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA;Society for Immunotherapy of Cancer and Executive Director, Inc., Milwaukee, WI, USA;Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle, WA, USA;

关键词: Sustained Virological Response;    Cancer Immunotherapy;    Multiparameter Flow Cytometry;    Immunological Monitoring;    CD54 Upregulation;   

DOI  :  10.1186/1479-5876-8-130

 received in 2010-12-01, accepted in 2010-12-07,  发布年份 2010

来源: Springer

【 摘 要 】

The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.

【 授权许可】

Unknown   
© Butterfield et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.